"At the end of the inspection, the facility received 9 observations,
with no repeat observations and mostly procedural in nature," Natco
Pharma said in a BSE filing.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-issues-9-observations-to-natco-pharmas-kothur-facility/articleshow/69673803.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment